University patents
Fewer than one-third of university patents are ultimately licensed.
Life sciences venture studio
From scientific discovery to durable company.
AVIVA brings decades of life sciences experience to your next company-building decision. We work alongside you from early research through financing and launch, helping your science move closer to patients.
Experienced people. Shared purpose. Built around your science.
Select a problem to see AVIVA's approach.
University / TTO
Which asset deserves the spinout?
AVIVA scores the evidence, compares readiness, and documents the spinout decision.
Selected leadership experience
24+Biotechnology companies supported across prior and current roles
$100M+Raised across prior ventures
15+Pharmaceutical product launches across prior roles
100+Years of combined pharma, biotech, technology, and investor experience
Figures reflect the leadership team's experience before and alongside AVIVA.
The commercialization gap
Promising science stalls when readiness goes unmeasured.
A patent, a strong pitch, or a financing round does not resolve the operating gaps that determine whether a company can advance. AVIVA makes those gaps visible early.
Clinical candidates
Fewer than 10 percent of drugs entering clinical trials are eventually approved.
Venture-backed startups
About three in four venture-backed startups never return investor capital.
Sources: NIH technology-transfer review, FDA drug-development primer, and Harvard Business School research (Wall Street Journal).
AVIVA Score™
A quantified standard for what to build next.
AVIVA Score™, our proprietary Company Formation Index, provides a structured assessment across three decision gates. The model is built around over 400 questions designed by a subject matter expert in technology transfer. Our team reviews the findings and helps you decide what to build next.
AI helps synthesize data and research IP or market information. It supports our experts' judgment; it does not determine the score on its own.
Research asset
Can the science support a company?
Spinout Readiness examines the conditions required to move from institutional research into an independent venture.
- IP ownership
- Freedom to operate
- Regulatory pathway
- Manufacturing feasibility
Financing decision
Can the company support institutional capital?
Investor Readiness identifies the operating and evidence gaps that can block a credible financing process.
- Proof-of-concept package
- Patent clock
- Management team
- Business model
Market entry
Can the company execute commercialization?
Commercial Readiness examines the decisions that shape access, channels, launch preparation, and commercial leadership. Payer strategy and sales channels, the two dominant failure modes, carry double weight.
- Payer strategy
- Sales channels
- Launch readiness
- Operating leadership
AVIVA Score™ free demo
Get your personalized assessment for free.
Follow an illustrative life sciences program through a five-step Commercial Readiness Assessment, from source materials to prioritized recommendations.
Try the free sampleSample programNeuroShield-17
1.8 / 5 readiness20+Domains
375+Checks
5Next actions
The AVIVA Pathway
One operating arc from research asset to launch-ready business.
The score shows what needs attention. The pathway organizes the work, the team, and the next milestone.
Diagnose
Determine whether the science is ready to leave the bench and support an independent venture.
Build
Form the entity and establish the intellectual-property, regulatory, and manufacturing foundation.
Strengthen
Close the gaps that block financing and assemble an operating team that can carry the plan.
Scale
Prepare payer strategy, commercial channels, launch execution, and leadership.
Who we serve
Guidance written for your side of the table.
Each audience page speaks to the decisions ahead of it.
Leadership
Meet the operators behind AVIVA.
The team brings experience across company formation, clinical development, financing, commercialization, operations, and production technology.
Dr. Stella K. Vnook
Founder, President & CEO
Life sciences executive with experience from early development through commercialization.
Robbin Miller
Director of Operations
Operations leader focused on infrastructure, compliance, and company execution.